CMS Open Payments · Program Year 2024
Route 92 Medical, Inc.
Route 92 Medical, Inc. reported $9,674,355.13 across General Payments, Research, and Ownership to 774 physicians and teaching hospitals across 812 transactions.
- $9.7M Top 10% payer
- All-tracks total
- 812 Above-median volume
- Transactions
- 774 Above-median reach
- Recipients
- +$328.3K
- General Payments vs PY2023
Route 92 Medical, Inc. reported $9,674,355.13 across all CMS Open Payments tracks (General + Research + Ownership) to 774 physicians and teaching hospitals in Program Year 2024 - ranking #180 of 1,925 reporting manufacturers (0.1% of the all-tracks industry total); General Payments alone were $704,691.25, averaging $12.5K per recipient.
How Route 92 Medical, Inc.'s $9.7M all-tracks total breaks down
Route 92 Medical, Inc.'s payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
45/100
Total payments
A
99/100
Transaction volume
F
16/100
Physician reach
F
16/100
Payment type diversity
D
50/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer route-92-medical-inc Route 92 Medical, Inc.
$9.7M · #180/1,925 · 0.1% industry · PY2024
- TOT $9.7M
- RANK #180
- SHARE 0.1%
- TXN 812
- RCP 774
- CAT 4
- GEN $704.7K
- ΔGEN +$328.3K
- TOP1 37.6%
- PY 2024
Volume peers
Nearest volume peer: EyePoint Pharmaceuticals US, Inc. ($9.7M)
Route 92 Medical, Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Route 92 Medical, Inc.'s CMS-reported General Payments increased by $328.3K (+87.2%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: ROUTE 92 MEDICAL, INC.PY2023: ROUTE 92 MEDICAL, INC.PY2024: Route 92 Medical, Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $376,394.51
- PY2024
- $704,691.25
What the Data Shows for Route 92 Medical, Inc.
The all-tracks total above combines three CMS reporting categories - General Payments, Research Payments, and Ownership/Investment interests - not one undifferentiated figure. For Route 92 Medical, Inc., that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. CMS publishes each Program Year's data roughly 12 months after the reporting period ends, so this reflects the most recently released cycle; see our methodology for how the tracks are standardized and compared across companies.
60 transactions worth $644.6K make "Consulting Fee" the top general-payment category in the 4-category breakdown below, 91.5% of General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
Across 4 types of general payments, Route 92 Medical, Inc.'s largest category was "Consulting Fee" at $644.6K - 91.5% of General Payments.
Route 92 Medical, Inc. reports 4 general-payment categories - the top three are Consulting Fee (91.5%), Food and Beverage (5.5%), and Travel and Lodging (3.0%). The remaining 1 category make up 0.0% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How Route 92 Medical, Inc. divides its payments
How the reported total splits across payment categories
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Consulting Fee | $644.6K | 60 | 91.5% |
| Food and Beverage | $38.9K | 672 | 5.5% |
| Travel and Lodging | $21.0K | 40 | 3.0% |
| Entertainment | $245.02 | 2 | 0.0% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $604,639.11 (85.8%) of $704,691.25 in this company's General Payments records across 290 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Route 92 Medical, Inc.
The five named recipients with the highest reported General Payments from this company
- 1
Fabio Settecase
$264,725.47 across 14 reported transactions
- 2
Warren Kim
$116,252.40 across 27 reported transactions
- 3
Matthew Alexander
$110,061.51 across 15 reported transactions
- 4
Joey English
$98,269.62 across 40 reported transactions
- 5
Ajit Puri
$15,330.11 across 9 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Route 92 Medical, Inc. ranks #180 of 1,925 by total payments (top 9% by spend) but spreads that money notably more broadly than its spend rank alone would suggest -- #727 of 1,838 by HHI (top 40% most concentrated), a wider distribution than most similarly sized payers.
View all 12 companies in this HHI neighborhood as a list
- Endogastric Solutions, Inc : $196.7K total payments, HHI 2176
- FUKUDA DENSHI Co., Ltd. : $8.8K total payments, HHI 2176
- imvaria inc. : $1.4K total payments, HHI 2173
- Biedermann Motech, Inc. : $7.7K total payments, HHI 2168
- Embecta Corp. : $245.4K total payments, HHI 2146
- Allerderm Laboratories : $9.2K total payments, HHI 2140
- Route 92 Medical, Inc. (this company) : $704.7K total payments, HHI 2140
- Braintree Laboratories, Inc. : $652.0K total payments, HHI 2132
- elliquence, LLC : $336.3K total payments, HHI 2127
- Tosoh Bioscience, Inc. : $290.85 total payments, HHI 2118
- Meridian Bioscience Inc. : $173.7K total payments, HHI 2110
- Alaska Medical Technologies, Llc : $3.2K total payments, HHI 2108
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Route 92 Medical, Inc.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Route 92 Medical, Inc..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Route 92 Medical, Inc..
Showing 6 of 1,924 companies with CMS-reported payment data.
Dermavant Sciences, Inc.
Supernus Pharmaceuticals, Inc.
H. Lundbeck A S
W. L. Gore & Associates, Inc.
Applied Medical Research, Inc
Put this to use
Route 92 Medical, Inc. ranks #180 of 1,925 by all-tracks total payments, led by "Consulting Fee".
- See where Route 92 Medical, Inc. sits among every top spender on the full leaderboard. Top 100 by total payments
- Compare "Consulting Fee" spend across every manufacturer, not just Route 92 Medical, Inc.. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.